Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer

It is well known that a phenomenon called hyperprogressive disease (HPD) often occurs during immunotherapy with immune checkpoint inhibitors. In the present case, we experienced a case of HPD in a potential metastatic thyroid tumour during immunotherapy. HPD can be life‐threatening depending on wher...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujita, Kohei, Araki, Norio, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2021
Materias:
Clinical Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506638/
https://www.ncbi.nlm.nih.gov/pubmed/34667615
http://dx.doi.org/10.1002/rcr2.866
_version_ 1784581734790070272
author Fujita, Kohei
Araki, Norio
Mio, Tadashi
author_facet Fujita, Kohei
Araki, Norio
Mio, Tadashi
author_sort Fujita, Kohei
collection PubMed
description It is well known that a phenomenon called hyperprogressive disease (HPD) often occurs during immunotherapy with immune checkpoint inhibitors. In the present case, we experienced a case of HPD in a potential metastatic thyroid tumour during immunotherapy. HPD can be life‐threatening depending on where it appears, so clinicians need to be careful.
format Online
Article
Text
id pubmed-8506638
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-85066382021-10-18 Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer Fujita, Kohei Araki, Norio Mio, Tadashi Respirol Case Rep Clinical Images It is well known that a phenomenon called hyperprogressive disease (HPD) often occurs during immunotherapy with immune checkpoint inhibitors. In the present case, we experienced a case of HPD in a potential metastatic thyroid tumour during immunotherapy. HPD can be life‐threatening depending on where it appears, so clinicians need to be careful. John Wiley & Sons, Ltd 2021-10-12 /pmc/articles/PMC8506638/ /pubmed/34667615 http://dx.doi.org/10.1002/rcr2.866 Text en © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Images
Fujita, Kohei
Araki, Norio
Mio, Tadashi
Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
title Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
title_full Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
title_fullStr Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
title_full_unstemmed Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
title_short Diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
title_sort diffuse goitre enlargement after immunotherapy for non‐small cell lung cancer
topic Clinical Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506638/
https://www.ncbi.nlm.nih.gov/pubmed/34667615
http://dx.doi.org/10.1002/rcr2.866
work_keys_str_mv AT fujitakohei diffusegoitreenlargementafterimmunotherapyfornonsmallcelllungcancer
AT arakinorio diffusegoitreenlargementafterimmunotherapyfornonsmallcelllungcancer
AT miotadashi diffusegoitreenlargementafterimmunotherapyfornonsmallcelllungcancer

Ejemplares similares